PLX PE Ratio & Valuation, Is PLX Overvalued

Historical Valuation

Protalix Biotherapeutics Inc (PLX) is now in the Fair zone, suggesting that its current forward PS ratio of 1.86 is considered Fairly compared with the five-year average of 5.74. The fair price of Protalix Biotherapeutics Inc (PLX) is between 1.37 to 2.98 according to relative valuation method.

Relative Value

Fair Zone

1.37-2.98

Current Price：2.07

Fair

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Protalix Biotherapeutics Inc (PLX) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Protalix Biotherapeutics Inc (PLX) has a current Price-to-Book (P/B) ratio of 2.64. Compared to its 3-year average P/B ratio of 16.16, the current P/B ratio is approximately -83.65% higher. Relative to its 5-year average P/B ratio of 21.28, the current P/B ratio is about -87.58% higher. Protalix Biotherapeutics Inc (PLX) has a Forward Free Cash Flow (FCF) yield of approximately -8.36%. Compared to its 3-year average FCF yield of -3.65%, the current FCF yield is approximately 128.79% lower. Relative to its 5-year average FCF yield of -14.65%, the current FCF yield is about -42.97% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for PLX competitors is 2.24, providing a benchmark for relative valuation. Protalix Biotherapeutics Inc Corp (PLX.A) exhibits a P/S ratio of 1.86, which is -16.95% above the industry average. Given its robust revenue growth of -97.65%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of PLX increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of PLX in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is PLX currently overvalued or undervalued?

What is Protalix Biotherapeutics Inc (PLX) fair value?

PLX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Protalix Biotherapeutics Inc (PLX) is between 1.37 to 2.98 according to relative valuation method.

How does PLX's valuation metrics compare to the industry average?

The average P/S ratio for PLX's competitors is 2.24, providing a benchmark for relative valuation. Protalix Biotherapeutics Inc Corp (PLX) exhibits a P/S ratio of 1.86, which is -16.95% above the industry average. Given its robust revenue growth of -97.65%, this premium appears unsustainable.

What is the current P/B ratio for Protalix Biotherapeutics Inc (PLX) as of Mar 25 2026?

As of Mar 25 2026, Protalix Biotherapeutics Inc (PLX) has a P/B ratio of 2.64. This indicates that the market values PLX at 2.64 times its book value.

What is the current FCF Yield for Protalix Biotherapeutics Inc (PLX) as of Mar 25 2026?

As of Mar 25 2026, Protalix Biotherapeutics Inc (PLX) has a FCF Yield of -8.36%. This means that for every dollar of Protalix Biotherapeutics Inc's market capitalization, the company generates -8.36 cents in free cash flow.

What is the current Forward P/E ratio for Protalix Biotherapeutics Inc (PLX) as of Mar 25 2026?

As of Mar 25 2026, Protalix Biotherapeutics Inc (PLX) has a Forward P/E ratio of 9.94. This means the market is willing to pay $9.94 for every dollar of Protalix Biotherapeutics Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Protalix Biotherapeutics Inc (PLX) as of Mar 25 2026?

As of Mar 25 2026, Protalix Biotherapeutics Inc (PLX) has a Forward P/S ratio of 1.86. This means the market is valuing PLX at $1.86 for every dollar of expected revenue over the next 12 months.

PLX Valuation